Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.70 |
| ▸ | RXRA | P19793 | 10/20 | 0.67 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.67 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19211402 | 0.86 | NOTUM (0.66) | NOTUMRXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL19211410 | 0.82 | NOTUM (0.76) | NOTUMRXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL19211430 | 0.82 | NOTUM (0.76) | NOTUMRXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL21792335 | 0.82 | NOTUM (1.00) | NOTUMKDM4EMAPT | |
| SCHEMBL19219673 | 0.82 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19211361 | 0.81 | RXRA (0.69) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL19219672 | 0.81 | RXRA (1.00) | RXRAGRIN1GRIN2B | |
| SCHEMBL19211413 | 0.80 | NOTUM (0.80) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL19211513 | 0.79 | RXRA (0.67) | NOTUMRXRAGRIN1GRIN2BKDM4E | |
| SCHEMBL19211436 | 0.78 | RXRA (0.70) | NOTUMRXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109071488-B | Substituted 1,2, 3-triazoles as NR 2B-selective NMDA modulators | 詹森药业有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-08 | — | — | US | disclosed |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-08 | — | — | US | disclosed |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-09 | — | — | US | disclosed |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-09 | — | — | US | disclosed |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-19 | — | — | US | disclosed |
| EP-3414233-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-12-19 | — | — | EP | disclosed |
| US-20180334451-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-22 | — | — | US | disclosed |
| US-10071988-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-11 | — | — | US | disclosed |
| WO-2017139428-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139428-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | WO | disclosed |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334451-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | NOTUM 4764/4885RXRA 2100/4885GRIN1 3/4885 |
| US-10766880-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | NOTUM 4764/4885RXRA 2100/4885GRIN1 3/4885 |
| US-10233173-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | NOTUM 4764/4885RXRA 2100/4885GRIN1 3/4885 |
| US-20170226089-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | NOTUM 4764/4885RXRA 2100/4885GRIN1 3/4885 |
| US-10071988-B2 | Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators | GRIN3A, GRIN3B, GRIN1 | NOTUM 4764/4885RXRA 2100/4885GRIN1 3/4885 |
| US-20190135791-A1 | SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS | GRIN3A, GRIN3B, GRIN1 | NOTUM 4764/4885RXRA 2100/4885GRIN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.